6Building A Drug Candidate MarketplaceGemsekiWhen biotech companies or academia make alliances with pharmaceutical companies, they face a plethora of difficulties; not having enough resources and connections to reach out global life science industry. There exists a huge asymmetry of information between small biotech companies and large pharmaceutical companies. The biotech companies and academia have great needs in licensing, partnering, making alliances and M&As to advance their researches but they lack the resources to proceed with these activities. This became a barrier to the innovation of the whole industry.Hideyuki Hirama incorporated Gemseki because he saw these problems."I wanted to contribute to the life science community using my finance background to enhance innovation," explains Hirama. "The industry needs to change, but there has been little effort to solve these issues."Armed with a finance background, and MBA degree from Harvard Business School, Hideyuki Hirama, President & CEO of Gemseki, chose to work in the life science industry and became one of the unique, most sought after leader owing to his diverse experience. Initiating Open InnovationGemseki has been trying to address these issues via its web-based platform "Drug Candidate Marketplace" to list available assets for partnering. Drug Candidate Marketplace lists the information of drug candidates, therapeutic targets and drug discovery technologies. Open innovation is needed more than ever in the life science industry and the platform, together with Hirama and his team's hands-on support, serves this purpose. "This can be a tool for partnering and close the information gap among players," he adds. "In addition, Gemseki has more than 15 members including Open innovation is needed more than ever in the life science industry and the platform, together with Hirama and his team's hands-on support, serves this purposeGemseki HP: gemseki.com/enDrug Candidate Marketplace: gemseki.com/en/drugcandidatemarket
< Page 5 | Page 7 >